000 01200 a2200361 4500
005 20250515232448.0
264 0 _c20110203
008 201102s 0 0 eng d
022 _a1750-7448
024 7 _a10.2217/imt.09.66
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMarkman, Ben
245 0 0 _aNew trends in epidermal growth factor receptor-directed monoclonal antibodies.
_h[electronic resource]
260 _bImmunotherapy
_cNov 2009
300 _a965-82 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAntibodies, Monoclonal
_xtherapeutic use
650 0 4 _aAntibodies, Monoclonal, Humanized
650 0 4 _aCetuximab
650 0 4 _aClinical Trials as Topic
650 0 4 _aErbB Receptors
_xantagonists & inhibitors
650 0 4 _aHumans
650 0 4 _aImmunotherapy
650 0 4 _aNeoplasms
_ximmunology
650 0 4 _aPanitumumab
650 0 4 _aProtein Engineering
650 0 4 _aSignal Transduction
700 1 _aCapdevila, Jaume
700 1 _aElez, Elena
700 1 _aTabernero, Josep
773 0 _tImmunotherapy
_gvol. 1
_gno. 6
_gp. 965-82
856 4 0 _uhttps://doi.org/10.2217/imt.09.66
_zAvailable from publisher's website
999 _c19978478
_d19978478